These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 22967188)

  • 1. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antipsychotics in bipolar disorders].
    Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
    Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
    Cavazzoni PA; Berg PH; Kryzhanovskaya LA; Briggs SD; Roddy TE; Tohen M; Kane JM
    J Clin Psychiatry; 2006 Jan; 67(1):107-13. PubMed ID: 16426096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine versus other atypical antipsychotics for schizophrenia.
    Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight change and metabolic effects of asenapine in patients with schizophrenia and bipolar disorder.
    Kemp DE; Zhao J; Cazorla P; Landbloom RP; Mackle M; Snow-Adami L; Szegedi A
    J Clin Psychiatry; 2014 Mar; 75(3):238-45. PubMed ID: 24499969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Metabolic side effects of risperidone in early onset schizophrenia].
    Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
    Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of olanzapine in adolescents with schizophrenia or bipolar I disorder: a pooled analysis of 4 clinical trials.
    Kryzhanovskaya LA; Robertson-Plouch CK; Xu W; Carlson JL; Merida KM; Dittmann RW
    J Clin Psychiatry; 2009 Feb; 70(2):247-58. PubMed ID: 19210948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials.
    Pringsheim T; Lam D; Ching H; Patten S
    Drug Saf; 2011 Aug; 34(8):651-68. PubMed ID: 21751826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.
    Mitchell M; Riesenberg R; Bari MA; Marquez E; Kurtz D; Falk D; Hardy T; Taylor CC; Mitchell CP; Cavazzoni P
    Clin Ther; 2006 Jun; 28(6):881-92. PubMed ID: 16860171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials.
    Edwards SJ; Smith CJ
    Clin Ther; 2009 Jun; 31 Pt 1():1345-59. PubMed ID: 19698898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
    Lao KS; He Y; Wong IC; Besag FM; Chan EW
    CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Stip E
    Expert Opin Drug Saf; 2012 Sep; 11(5):713-32. PubMed ID: 22913713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine for schizophrenia.
    Duggan L; Fenton M; Rathbone J; Dardennes R; El-Dosoky A; Indran S
    Cochrane Database Syst Rev; 2005 Apr; (2):CD001359. PubMed ID: 15846619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
    Almandil NB; Liu Y; Murray ML; Besag FM; Aitchison KJ; Wong IC
    Paediatr Drugs; 2013 Apr; 15(2):139-50. PubMed ID: 23519708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.